Tumour necrosis factor inhibitors

Medical Journal of Australia

Volumn 183, Issue 4, 2005, Pages 205-208

  Nash, Peter T ^a,b   Florin, Timothy H J ^a,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b NAMBOUR GENERAL HOSPITAL   (Australia)

^c MATER ADULT HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; BCG VACCINE; CERTOLIZUMAB PEGOL; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ISONIAZID; MERCAPTOPURINE; METHOTREXATE; PLACEBO; PROTEIN P55; STEROID; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ANKYLOSING SPONDYLITIS; APLASTIC ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; BONE RADIOGRAPHY; CHRONIC INFLAMMATION; CLINICAL TRIAL; CROHN DISEASE; DEMYELINATING DISEASE; DEMYELINATION; DISEASE EXACERBATION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FOLLOW UP; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; INFECTIOUS ARTHRITIS; INJECTION SITE REACTION; LONG TERM CARE; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE SCLEROSIS; MYCOSIS; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; OPTIC NERVE DISEASE; PANCYTOPENIA; PATHOGENESIS; PNEUMOCYSTOSIS; PROSTHESIS INFECTION; PROTEIN FUNCTION; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEPSIS; SIDE EFFECT; SKIN INDURATION; SYMPTOMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULOSIS;

EID: 23844558948     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2005.tb06998.x     Document Type: Article

References (34)

1. Choy E, Panayi G. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907-916.
2. ten Hove T, Van Montfrans C, Peppelenbosch M, Van Deventer SJ. Infliximab treatment induces apoptosis of activated lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50: 206-211.
3. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 542-553.
4. Keystone E, Schiff M, Kremer J, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicentre, randomized, double blind placebo controlled trial. Arthitis Rheum 2004: 50; 353-363.
5. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis 2004; 63 Suppl 2: ii2-ii12.
6. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130: 478-486.
7. Klareskog L, van der Heijde D, de Jager JP, et al. TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-681.
8. van de Putte L, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic therapy drug treatment has failed. Ann Rheum Dis 2004; 63: 508-516.
9. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-1411.
10. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-1602.
11. National Health and Medical Research Council. Guide to the development implementation of clinical practice guidelines. Canberra: NHMRC, 1999. Available at: http://www.health.gov.au/nhmrc/publications/pdf/cp30.pdf (accessed Jul 2005).
12. Lovell DJ, Giannini EH, Reiff A, et al. Pediatric Rheumatology Collaborative Study Group. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003; 48: 218-226.
13. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264-2272.
14. Antoni C, Kavanagh A, Gladman D, Wassenburg B. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analysis after 1 year [abstract]. Ann Rheum Dis 2005. In press.
15. Kavanagh A, Ritchlin C, Malaise M, et al. Adalimumab treatment with and without methotrexate in patients with moderate to severe psoriatic arthritis: results from the Adept trial [abstract]. Ann Rheum Dis 2005. In press.
16. Baraliakos X, Listing J, Rudwaleit M, et al. Radiographic progression in patients with ankylosing spondylitis after two years of treatment with tumour necrosis factor-a antibody infliximab. Ann Rheum Dis 2005; Mar 18; [Epub ahead of print].
17. Davis JC Jr, Van Der HD, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 3230-3236.
18. Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003; 62: 817-824.
19. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-1035.
20. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-1405.
21. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-413.
22. Winter TA, Wright J, Ghosh S, et al. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Aliment Pharmacol Ther 2004; 20: 1337-1346.
23. Sandborn W, Hanauer S, Lukas M, et al. Induction and maintenance of clinical remission and response in subjects with Crohn's disease treated with a 6-month open-label period with fully human anti-TNFa monoclonal antibody adalimumab (Humara) [abstract]. Gastroenterology 2005; 128 (Suppl 2): A-1 11. (Abstract 723.)
24. Rutgeerts P, Feagan BG, Olson A, et al. A randomized placebo-controlled trial for active ulcerative colitis: ACT 1 trial [abstract]. Gastroenterology 2005; 128 (Suppl 2): A-105. (Abstract 689.)
25. Li J, Roche P, Spencer J, et al. National Tuberculosis Advisory Committee Communicable Disease Network Australia. Tuberculosis notifications in Australia, 2003. Commun Dis Intell 2004; 28: 464-473.
26. Mortimore M, Gibson PR, Selby WS, et al; The Infliximab User Group. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? Intern Med J 2001; 31: 146-150.
27. Ochsenkuhn T, Goke B, Sackmann M. Combining infliximab with 6-mercaptopurine /azathioprine for fistula therapy in Crohn's disease. Am J Gastroenterol 2002; 97: 2022-2025.
28. Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 2003; 17: 1451-1457.
29. Giles J, Bathon J. Serious infections associated with anticytokine therapies in the rheumatic diseases. J intensive Care Med 2004; 19: 320-334.
30. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 372-379.
31. Ormerod LP. Assessing risk and managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNFalpha treatment. Cytokine 2004; 28: 179-181.
32. Tauber WB. Serious adverse effects associated withthe use of anti-TNF alpha drugs. Available at: http://www.fda.gov/cder/present/DIA2004/ Tauber_files/frame.htm (accessed Jul 2005).
33. Baecklund E, Ekbom A, Sparen P, et al. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case control study. BMJ 1998; 317: 180-181.
34. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18 572 patients. Arthritis Rheum 2004; 50: 1740-1751.